Our study revealed a decreasing trend but no statistically significant difference in either the seroconversion rate or percent inhibition in patients receiving chemotherapy three months prior to or during the vaccination period in terms of neutralization antibodies for both the wild-type and Omicron variants, regardless of leukopenia, neutropenia, or lymphopenia.
← all excerpts
Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.
1
—
—